Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | TLR2 | O60603 | 3/20 | 0.56 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.56 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362262 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL29401707 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL2267346 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL30885878 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL12040103 | 1.00 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL1000135 | 0.99 | KMT2A (0.60) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL7392221 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL7815145 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL17669898 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL30441695 | 0.97 | MDM2 (0.57) | KMT2AMDM2TLR2TLR1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-12383560-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2025134068-A1 | ANTIBODY DRUG CONJUGATES TARGETING PROTEINOPATHIES, AND USES THEREOF | AC IMMUNE SA (CH) | 2025-06-26 | — | — | WO | disclosed |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| WO-2025128626-A1 | HYBRID PEPTIDE COMPOUNDS HAVING A MODIFIED LYSINE RESIDUE | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025128624-A2 | HYBRID PEPTIDE COMPOUNDS HAVING A SUBSTITUTED TRYPTOPHAN RESIDUE OR A TERMINAL SUBSTITUENT | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| US-5386011-A | Antiinflammatory agents; also, peptidomimetic compounds, i,e., agonists, having immunoregulatory effect against infections and cancer | ABBOTT LABORATORIES (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0564588-A4 | HEXA- AND HEPTAPEPTIDE ANAPHYLATOXIN-RECEPTOR LIGANDS | — | 1993-12-29 | — | — | EP | disclosed |
| EP-0564588-A1 | HEXA- AND HEPTAPEPTIDE ANAPHYLATOXIN-RECEPTOR LIGANDS. | ABBOTT LAB (US) | 1993-10-13 | — | — | EP | disclosed |
| WO-1992011858-A1 | HEXA- AND HEPTAPEPTIDE ANAPHYLATOXIN-RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | CD47, ABCB1, EGFR | KMT2A 2537/4885MDM2 2059/4885TLR2 2732/4885 |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885MDM2 1169/4885TLR2 4438/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | KMT2A 1606/4885MDM2 2085/4885TLR2 3185/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | KMT2A 3406/4885MDM2 3730/4885TLR2 2757/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | KMT2A 719/4885MDM2 384/4885TLR2 4179/4885 |
| US-12383560-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | KMT2A 792/4885MDM2 2551/4885TLR2 4839/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | KMT2A 2434/4885MDM2 3219/4885TLR2 1153/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | KMT2A 4429/4885MDM2 2032/4885TLR2 20/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | KMT2A 37/4885MDM2 2883/4885TLR2 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.